Rates of Pathologic Complete Response (pCR) According to Levels of Tumor-Infiltrating Lymphocytes (TILs) (A) and Immunoglobulin G (IgG) Gene Expression Signature (B)
Both variables were divided by tertiles to illustrate their association with pCR. HL indicates trastuzumab plus lapatinib; TH, weekly paclitaxel plus trastuzumab; THL, TH plus lapatinib; and TL, weekly paclitaxel plus lapatinib.Thirty-six of 202 iGESs (17.8%) were also significantly associated with pCR independently of the treatment group and study (eTable 4 in the 